GlaxoSmithKline PLC(GSK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GSK GlaxoSmithKline PLC

Pre-Mkt 06-26 09:10:19 EDT

51.89

+0.80

+1.57%

盘前51.60

-0.29-0.56%

09:09 EDT

High52.48	Low51.72	Vol3.58M
Open51.96	D1 Closing51.09	Amplitude1.49%
Mkt Cap105.01B	Tradable Cap101.02B	Total Shares2.02B
T/O186.01M	T/O Rate0.18%	Tradable Shares1.95B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"GlaxoSmithKline PLC","latestPrice":51.89,"timestamp":1782417600000,"preClose":51.09,"halted":0,"volume":3575366,"hourTrading":{"tag":"盘前","latestPrice":51.6,"preClose":51.89,"latestTime":"09:09 EDT","volume":19956,"amount":1028863.70916,"timestamp":1782479346626,"change":-0.29,"changeRate":-0.005589,"amplitude":0.010021},"delay":0,"changeRate":0.01565864161284003,"floatShares":1946891708,"shares":2023763538,"eps":3.736205,"marketStatus":"Pre-Mkt","change":0.8,"latestTime":"06-26 09:10:19 EDT","open":51.955,"high":52.48,"low":51.72,"amount":186006539.08285,"amplitude":0.014876,"askPrice":51.61,"askSize":1400,"bidPrice":51.57,"bidSize":600,"shortable":3,"etf":0,"ttmEps":3.736205,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782480600000},"marketStatusCode":1,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":51.89,"dividendRate":0.034189,"preHourTrading":{"tag":"盘前","latestPrice":51.6,"preClose":51.89,"latestTime":"09:09 EDT","volume":19956,"amount":1028863.70916,"timestamp":1782479346626,"change":-0.29,"changeRate":-0.005589,"amplitude":0.010021},"postHourTrading":{"tag":"盘后","latestPrice":51.9802,"preClose":51.89,"latestTime":"18:18 EDT","volume":185411,"amount":9691340.6468,"timestamp":1782425932558,"change":0.0902,"changeRate":0.001738,"amplitude":0.002124},"volumeRatio":0.9585616776975918,"optionData":{"bulkOrders":[{"symbol":"GSK","call":true,"expireDate":1787284800000,"strike":"60.0","timestamp":1782406169662,"price":0.3,"volume":1808,"amount":54240,"type":"+"}]},"impliedVol":0.2993,"impliedVolPercentile":0.532},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"2646027078","title":"GSK Advances BALANCE Trial: New IBS Drug Candidate Moves Through Mid‑Stage Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646027078","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646027078?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:31","pubTimestamp":1782405113,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running the BALANCE Phase 2b study to test camlipixa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-advances-balance-trial-new-ibs-drug-candidate-moves-through-midstage-testing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-advances-balance-trial-new-ibs-drug-candidate-moves-through-midstage-testing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1829250122.USD","BK4007","GSK.UK","BK4532","GSK","GSKH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646020628","title":"GSK’s MODIFY Asthma Trial: Early Biologic Bet With Long-Term Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2646020628","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646020628?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:31","pubTimestamp":1782405105,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running the Phase 3b/4 MODIFY study to test early us...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-modify-asthma-trial-early-biologic-bet-with-long-term-upside-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-modify-asthma-trial-early-biologic-bet-with-long-term-upside-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU1829250122.USD","BK4007","GSK.UK","BK4585","GSK","BK4532","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646480230","title":"GSK Rallies Thursday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2646480230","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646480230?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:09","pubTimestamp":1782403740,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of GSK PLC  advanced 1.72% to GBP19.84 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index  rising 0.65% to 10,529.89.GSK PLC closed 13.08% short of its 52-week high of GBP22.82, which the company reached on February 18th.Trading volume totaled 6.8 million, compared to the 50-day average of 7.5 million.Data source: Dow Jones Market Data, FactSet Dow Jones NewswiresJune 25, 2026 12:09 ET Copyright  2026 Dow Jones & Company, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646809159","title":"GSK to Deliver Earnings Growth over Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2646809159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646809159?lang=en_us&edition=fundamental","pubTime":"2026-06-25 22:37","pubTimestamp":1782398220,"startTime":"0","endTime":"0","summary":"1437 GMT - GSK is poised to deliver growth in core earnings per share every year over the coming decade, as the loss of a key HIV patent should have less of an impact than many fear, Bernstein analysts say in a research note. The U.K. drugmaker is developing three new HIV products that should improve its sales prospects in the first half of the 2030s, according to Bernstein. The new products and the difficulty of manufacturing cabotegravir, the active ingredient in HIV drugs that is due to lose U.S. patents in 2029 and 2030, means the sales erosion from the patent should be less pronounced than expected, the analysts ay. Bernstein says it raises its core EPS forecast for GSK over the 2026-35 period by up to 25% and now projects growth every year. Shares rise 1.7%.  Dow Jones NewswiresJune 25, 2026 10:37 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646824383","title":"Gsk's HIV Franchise Seems Underappreciated","url":"https://stock-news.laohu8.com/highlight/detail?id=2646824383","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646824383?lang=en_us&edition=fundamental","pubTime":"2026-06-25 14:06","pubTimestamp":1782367560,"startTime":"0","endTime":"0","summary":"0605 GMT - HIV treatments look set to undergo a major transformation in the coming decades, and GSK's potential in this market seems underappreciated, Bernstein analysts say in a research note. With Britain's GSK and American rival Gilead Sciences commanding a combined 90% share of the U.S. HIV market, this is essentially a duopoly, according to Bernstein. Existing HIV drugs are already very effective, but upcoming innovations that will help move patients to long-acting injectable drugs from daily tablets is expected to drive future market growth, the analysts say. The U.S. HIV market is expected to grow to $37 billion in 2040, up from $26 billion last year, with GSK's share projected to rise to 44% from 26% over the same time horizon, they estimate.  Dow Jones NewswiresJune 25, 2026 02:06 ET Copyright  2026 Dow Jones & Company, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK.UK","SG9999015986.USD","BK4566","GSKH","BK4568","IE00B19Z3B42.SGD","LU0058720904.USD","LU0823416689.USD","IE0002270589.USD","BK4550","LU0289739699.SGD","BK4585","LU1674673691.USD","LU2089984988.USD","SG9999015952.SGD","BK4583","LU0122379950.USD","IE00B7SZLL34.SGD","GSK","BK4532","LU1066053197.SGD","LU0234570918.USD","LU1037948897.HKD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU1839511570.USD","LU1934455863.HKD","BK4139","LU1061106388.HKD","GILD","IE00B19Z3581.USD","LU0320765992.SGD","LU1037948541.HKD","BK4588","LU1674673428.USD","IE00BSNM7G36.USD","IE00B3T34201.USD","SG9999015945.SGD","BK4007","LU1023059063.AUD","LU0861579265.USD","LU2324357040.USD","IE00BKVL7J92.USD","LU1829250122.USD","LU0114720955.EUR","BK4578","LU1066051498.USD","LU1934455194.USD","SG9999015978.USD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646849382","title":"Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646849382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646849382?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:55","pubTimestamp":1782334518,"startTime":"0","endTime":"0","summary":"Bernstein analyst Jeffrey Walch maintained a Buy rating on GlaxoSmithKline yesterday and set a price target of p2,630.00. The company’s shares clos...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-buy-rating-on-glaxosmithkline-gsk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-buy-rating-on-glaxosmithkline-gsk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646812246","title":"GSK Revamps Belantamab Dosing in New Multiple Myeloma Study: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2646812246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646812246?lang=en_us&edition=fundamental","pubTime":"2026-06-25 00:31","pubTimestamp":1782318667,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK Tests New Dosing for Key Myeloma Drug in Phase 2 Trial. This new st...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-revamps-belantamab-dosing-in-new-multiple-myeloma-study-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-revamps-belantamab-dosing-in-new-multiple-myeloma-study-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4211","BK4007","GSK.UK","LU1829250122.USD","BK4532","GSKH","GSK","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646781288","title":"GSK Unit Launches Tender Offer for Nuvalent Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2646781288","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646781288?lang=en_us&edition=fundamental","pubTime":"2026-06-25 00:02","pubTimestamp":1782316952,"startTime":"0","endTime":"0","summary":"GSK  said Wednesday its Harmony Row Acquisition unit commenced a tender offer to purchase all outstanding Class A and Class B shares of Nuvalent  for $124 per share in cash.Following the consummation of the offer, the unit will merge into Nuvalent, which will continue as a direct wholly-owned subsidiary of GlaxoSmithKline LLC.Nuvalent's board of directors recommended that stockholders accept the offer and tender their shares, GSK said.The tender offer and withdrawal rights will expire on July 14, the company added.Price: 51.20, Change: -0.87, Percent Change: -1.67","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","GSK","GSKH","BK4532","NUVL","GSK.UK","LU1829250122.USD","BK4585","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645811812","title":"GSK Discloses Executive Notional ADS Acquisition by U.S. President","url":"https://stock-news.laohu8.com/highlight/detail?id=2645811812","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645811812?lang=en_us&edition=fundamental","pubTime":"2026-06-24 22:32","pubTimestamp":1782311549,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has disclosed a transaction involving Maya Martinez-Davis, President of its U.S. business, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-discloses-executive-notional-ads-acquisition-by-u-s-president?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-discloses-executive-notional-ads-acquisition-by-u-s-president?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","GSK","BK4007","GSKH","LU1829250122.USD","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645781620","title":"GSK launches $124-per-share tender offer to acquire oncology developer Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2645781620","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645781620?lang=en_us&edition=fundamental","pubTime":"2026-06-24 21:58","pubTimestamp":1782309489,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has launched a cash tender offer, through its subsidiary Harmony Row Acquisition Co., to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-launches-124-per-share-tender-offer-to-acquire-oncology-developer-nuvalent?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-launches-124-per-share-tender-offer-to-acquire-oncology-developer-nuvalent?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","BK4007","GSK","LU1829250122.USD","BK4539","BK4585","BK4588","NUVL","BK4139","GSKH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645830773","title":"GSK Climbs Tuesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2645830773","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645830773?lang=en_us&edition=fundamental","pubTime":"2026-06-24 00:09","pubTimestamp":1782230940,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of GSK PLC  advanced 1.71% to GBP19.58 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index  falling 0.09% to 10,428.85.GSK PLC closed 14.22% short of its 52-week high of GBP22.82, which the company achieved on February 18th.Trading volume totaled 4.8 million, compared to the 50-day average of 7.5 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645837762","title":"GSK board members boost holdings with coordinated share purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2645837762","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645837762?lang=en_us&edition=fundamental","pubTime":"2026-06-23 23:07","pubTimestamp":1782227251,"startTime":"0","endTime":"0","summary":"An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has disclosed a series of share purchases by its senior board members, including...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-board-members-boost-holdings-with-coordinated-share-purchases?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-board-members-boost-holdings-with-coordinated-share-purchases?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","GSK","BK4007","LU1829250122.USD","BK4588","GSK.UK","GSKH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645888836","title":"GSK's Nuvalent Deal Could Be Rare Case of Profitable Oncology Acquisition -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2645888836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645888836?lang=en_us&edition=fundamental","pubTime":"2026-06-23 13:58","pubTimestamp":1782194280,"startTime":"0","endTime":"0","summary":"0557 GMT - GSK's proposed acquisition of Nuvalent could be a rare case of an oncology deal by a big pharmaceutical company at an excellent price that turns out to be profitable, Bernstein analysts say in a research note. Nuvalent's most advanced products--lung-cancer drugs candidates neladalkib and zidesamtinib--could generate total peak revenue of $9.8 billion, according to Bernstein. This is 56% higher than the current consensus forecast, the analysts say. The incremental sales should be very profitable for GSK, which leads Bernstein to estimate Nuvalent could lift GSK's 2036 adjusted EPS by 18%. \"We thus see this [acquisition] as another crucial piece in the jigsaw which restores GSK to sustainable growth and transforms investors' perceptions,\" the analysts say. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH","BK4139","BK4007","BK4585","GSK","BK4539","BK4588","LU1829250122.USD","NUVL","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645731440","title":"GSK Expands Treasury Stock Position with June Share Buybacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2645731440","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645731440?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:24","pubTimestamp":1782138247,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK has continued its ongoing share buyback programme, repurchasing more than one mill...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-expands-treasury-stock-position-with-june-share-buybacks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-expands-treasury-stock-position-with-june-share-buybacks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","BK4007","LU1829250122.USD","BK4588","GSKH","GSK","BK4585","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644080970","title":"GSK Targets Relapsed B-Cell Lymphoma With New Early-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644080970","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644080970?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:36","pubTimestamp":1781800606,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The study titled “A Phase 1/2 Open-label, Multi-center Study to Evaluat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-targets-relapsed-b-cell-lymphoma-with-new-early-stage-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-targets-relapsed-b-cell-lymphoma-with-new-early-stage-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4532","GSK.UK","GSKH","GSK","LU1829250122.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644208015","title":"GSK’s ZEAL-1L Lung Cancer Trial Delivers Mixed Readout With Limited Upside for Niraparib","url":"https://stock-news.laohu8.com/highlight/detail?id=2644208015","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644208015?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:30","pubTimestamp":1781800252,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK has reported results for ZEAL-1L, a Phase 3 trial officially titled...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-zeal-1l-lung-cancer-trial-delivers-mixed-readout-with-limited-upside-for-niraparib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-zeal-1l-lung-cancer-trial-delivers-mixed-readout-with-limited-upside-for-niraparib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZEAL","BK4585","BK4588","GSKH","BK4532","LU1829250122.USD","GSK","GSK.UK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644224087","title":"GSK Slips Thursday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2644224087","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644224087?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:07","pubTimestamp":1781798820,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of GSK PLC  shed 2.51% to GBP19.23 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index  falling 1.04% to 10,399.70.GSK PLC closed 15.73% below its 52-week high of GBP22.82, which the company reached on February 18th.Trading volume totaled 4.7 million, compared to the 50-day average of 7.4 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644723527","title":"Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644723527","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644723527?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:36","pubTimestamp":1781714160,"startTime":"0","endTime":"0","summary":"First and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are trea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313706/0/en/Utebzi-tebipenem-pivoxil-approved-in-the-US-for-adults-with-complicated-urinary-tract-infections-cUTIs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AP","BK4007","GSK","BK4588","BK4585","BK4532","GSK.UK","LU1829250122.USD","BK4006","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644740373","title":"GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2644740373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644740373?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:00","pubTimestamp":1781712056,"startTime":"0","endTime":"0","summary":"GSK  and Spero Therapeutics  said Wednesday that the US Food and Drug Administration has approved Utebzi as treatment for complicated urinary tract infections, including pyelonephritis, in adults.Utebzi, or tebipenem pivoxil, is the first and only oral carbapenem antibiotic approved in the US and is expected to become available by the end of 2026, the companies said.The approval was based on phase 3 trial data showing Utebzi's non-inferiority to intravenous imipenem-cilastatin, with tebipenem pivoxil achieving an overall success rate of 58.5% against 60.2% for imipenem-cilastatin, according to a statement. Tebipenem pivoxil's safety profile is also \"generally similar\" to that of imipenem-cilastatin, the companies said.GSK shares were up about 1%, while Spero stock was down more than 14% in Wednesday trading.Price: 52.72, Change: +0.50, Percent Change: +0.96","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","SPRO","BK4139","LU1829250122.USD","GSK","LABU","BK4539","BK4588","LENZ","BK4585","BK4532","GSKH","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644674796","title":"GSK, Spero Therapeutics announce FDA approval of Utebzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2644674796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644674796?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:17","pubTimestamp":1781709438,"startTime":"0","endTime":"0","summary":"GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the Food and Drug Administration has approved Utebzi, an oral antibiotic for the treatme...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-spero-therapeutics-announce-fda-approval-of-utebzi-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-spero-therapeutics-announce-fda-approval-of-utebzi-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSKH","GSK","LU1829250122.USD","LABU","BK4139","LENZ","SPRO","BK4007","BK4539","BK4585","BK4588","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":0.0241},{"period":"1month","weight":0.0076},{"period":"3month","weight":-0.0362},{"period":"6month","weight":0.0573},{"period":"1year","weight":0.3555},{"period":"ytd","weight":0.0581}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.158},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.2095},{"period":"ytd","weight":0.0768}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.013809},{"month":2,"riseRate":0.478261,"avgChangeRate":0.001243},{"month":3,"riseRate":0.608696,"avgChangeRate":0.019112},{"month":4,"riseRate":0.659574,"avgChangeRate":0.030828},{"month":5,"riseRate":0.404255,"avgChangeRate":-0.008644},{"month":6,"riseRate":0.595745,"avgChangeRate":0.010011},{"month":7,"riseRate":0.543478,"avgChangeRate":0.003945},{"month":8,"riseRate":0.586957,"avgChangeRate":0.005806},{"month":9,"riseRate":0.521739,"avgChangeRate":0.005973},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013062},{"month":11,"riseRate":0.478261,"avgChangeRate":0.009917},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014188}],"exchange":"NYSE","name":"GlaxoSmithKline PLC","nameEN":"GlaxoSmithKline PLC","securityTypeName":"DR","adrRate":"1:2"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GlaxoSmithKline PLC(GSK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GlaxoSmithKline PLC(GSK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GlaxoSmithKline PLC,GSK,GlaxoSmithKline PLC股票,GlaxoSmithKline PLC股票老虎,GlaxoSmithKline PLC股票老虎国际,GlaxoSmithKline PLC行情,GlaxoSmithKline PLC股票行情,GlaxoSmithKline PLC股价,GlaxoSmithKline PLC股市,GlaxoSmithKline PLC股票价格,GlaxoSmithKline PLC股票交易,GlaxoSmithKline PLC股票购买,GlaxoSmithKline PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GlaxoSmithKline PLC(GSK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GlaxoSmithKline PLC(GSK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}